Versatility in Dosage Options Mounjaro offers a range of dosage options, allowing healthcare providers to customize the treatment based on an individual's specific needs and response
Glycaemic efficacy Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA 1c (MD [95% CI]: 21.61 mmol/mol [23.26 to 19.97] [1.96% (2.11 to 1.82)]), followed by tirzepatide 10 mg (20.19 mmol/mol [21.89 to 18.48] [1.84% (1.99 to 1.69)]), semaglutide 2.0 mg (17.74 mmol/mol [22.03 to 13.45] [1.59% (1.95 to 1.22)]), tirzepatide 5 mg (17.60 mmol/mol [19.36 to 15.84] [1.60% (1.75 to 1.44)]), semaglutide 1.0 mg (15.25 mmol/mol [16.73 to 13.77] [1.39% (1.52 to 1.26)]) and semaglutide 0.5 mg (12.00 mmol/mol [13.74 to 10.26] [1.09% (1.24 to 0.94)]) (Fig
Novo Nordisk also plans to introduce two new, lower-priced brand-name products in Canada: Plosbrio and Poviztra as chemically identical alternatives to Ozempic and Wegovy, respectively
While these two drugs work similarly, they arent the same
It is the ultimate "better together" scenario
Here is where it gets more nuanced